{
    "clinical_study": {
        "@rank": "149655", 
        "arm_group": [
            {
                "arm_group_label": "Cases", 
                "description": "Patients with symptomatic peptic ulcer (UPU)"
            }, 
            {
                "arm_group_label": "Control group", 
                "description": "Control group without symptomatic peptic ulcer (UPU)."
            }
        ], 
        "brief_summary": {
            "textblock": "The analyses are conducted in a previous population-based cohort study  using The Health\n      Improvement Network database in the UK (Cai et al 2009).The aims of the post hoc analyses\n      are:\n\n      To estimate the relative risk of uncomplicated symptomatic peptic ulcer (UPU) associated\n      with use of low dose aspirin (ASA) and other anti-inflammatory drugs (NSAIDs, steroids) in\n      the general population To estimate the dose-response and duration-response associated with\n      use of these drugs To estimate the relative risk of UPU associated with naive/non-naive use\n      of low dose ASA in the general population To evaluate the effect of proton pump inhibitors\n      (PPI) (alone or in combination with anti-inflammatory drugs) on the occurrence of UPU in the\n      general population To investigate the management of low dose ASA/oral antiplatelets after\n      UPU"
        }, 
        "brief_title": "Risk of Uncomplicated Peptic Ulcer in the General Population", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Peptic Ulcer (Iowa Type {107680.0010})", 
        "condition_browse": {
            "mesh_term": [
                "Peptic Ulcer", 
                "Ulcer"
            ]
        }, 
        "detailed_description": {
            "textblock": "Risk of uncomplicated peptic ulcer in the general population"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        - Patients aged 40-84 years in 1997-2005  ( see study population description)\n\n        Exclusion Criteria:\n\n        - Patients aged below age 40 and 85 years and above ( see study population description)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "84 Years", 
            "minimum_age": "40 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The study is conducted using The Health Improvement Network database in the UK. Patients\n        aged 40-84 years between January 1997 and December 2005 with a registration status of\n        permanent or deceased, who were enrolled for at least 2 years with a GP and had 1 year of\n        electronic prescription history. Patients with a code for cancer, peptic ulcer (both\n        uncomplicated and complicated), upper GI bleeding, oesophageal varices, Mallory-Weiss\n        disease, alcohol abuse, liver disease, or coagulopathies before beginning date were\n        excluded from the source population. All patients in the study population were followed up\n        until the end of the study period (December 2005), or until they reached the age of 85,\n        died, met any of the exclusion criteria (including receiving a diagnosis of complicated\n        peptic ulcer disease), or received a diagnosis of uncomplicated peptic ulcer\n        disease.Patient records were manually reviewed to validate cases."
            }
        }, 
        "enrollment": {
            "#text": "4000", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01888588", 
            "org_study_id": "D5040N00006"
        }, 
        "intervention": {
            "arm_group_label": [
                "Cases", 
                "Control group"
            ], 
            "description": "Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use", 
            "intervention_name": "Risk of symptomatic peptic ulcer", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Uncomplicated peptic ulcer", 
            "Low dose aspirin (ASA)", 
            "Acid-suppressing drugs", 
            "Epidemiology"
        ], 
        "lastchanged_date": "July 1, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madrid", 
                    "country": "Spain"
                }, 
                "name": "Research Site"
            }
        }, 
        "location_countries": {
            "country": "Spain"
        }, 
        "number_of_groups": "2", 
        "official_title": "Risk of Uncomplicated Peptic Ulcer in the General Population", 
        "overall_official": {
            "affiliation": "CEIFE (Centro Espanol de Investigacion Farmacoepidemiologica - Spanish Centre for Pharmacoepidemiologic Research )", 
            "last_name": "Luis A Garcia Rodriguez, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Oversight Authority: Not applicable", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Relative risk (ratio) of UPU associated with current use of the different types of drugs versus non-use.", 
                "measure": "Relative risk (ratio) of uncomplicated peptic ulcer (UPU) associated with low dose ASA, other antiinflammatory drugs and other common drugs for chronic diseases(paracetamol, SSRI, tricyclic antidepressants, anticoagulants, acid suppressing drugs)", 
                "safety_issue": "No", 
                "time_frame": "From Januar 1 1997 till December 31 2005, an expected average of 4 years."
            }, 
            {
                "measure": "Management of aspirin after uncomplicated peptic ulcer (UPU).", 
                "safety_issue": "No", 
                "time_frame": "From January 1, 1997 till december 31, 2005, an average of 4 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01888588"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "AstraZeneca", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AstraZeneca", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Retrospective", 
        "study_type": "Observational", 
        "verification_date": "July 2013"
    }
}